Carfilzomib clinical trials
Also written Kyprolis and PR-171.
Its developmentBy 5 companies, company by company33 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.How each study uses carfilzomib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the carfilzomib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 20 Jul 2012 · KYPROLIS · NDA 202714 (FDA, Drugs@FDA)
- European Union
- 19 Nov 2015 · Kyprolis · EMEA/H/C/003790 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
157 studies that test it; most in 2013 (22)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 6 |
| 2011 | 10 |
| 2012 | 11 |
| 2013 | 22 |
| 2014 | 17 |
| 2015 | 12 |
| 2016 | 4 |
| 2017 | 10 |
| 2018 | 8 |
| 2019 | 14 |
| 2020 | 6 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 38 · Other 119
Amgen (23) · M.D. Anderson Cancer Center (9) · University of Chicago (7) · National Cancer Institute (NCI) (5) · Hackensack Meridian Health (5) · Memorial Sloan Kettering Cancer Center (5) · Emory University (5) · Mayo Clinic (4)
Often tested with
Tested in the same studies.
Dexamethasone (69) · Lenalidomide (25) · Daratumumab (18) · Pomalidomide (15) · Cyclophosphamide (11) · Melphalan (6) · Bortezomib (5) · Isatuximab (5)
Related medicines
As reviewed, each with the page that says it.
- One of Proteasome inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 5 phase 3 studies under way
Carfilzomib is the comparator. A study of two new drugs counts under both.
- 1Anitocabtagene autoleucel · Kite, A Gilead Company · next primary completion Jul 2028
- 1Cevostamab · Hoffmann-La Roche · next primary completion Nov 2028
- 1Etentamig · AbbVie · next primary completion Feb 2033
- 1Pomalidomide · AbbVie · next primary completion Feb 2033
- 1Elranatamab · Pfizer
- 1Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F · AstraZeneca · next primary completion Jun 2028
Reaching primary completion within a year · 20, 3 in phase 3
Studies that test carfilzomib, phase 3 first.
- Dec 2026Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)Phase 3 · University of Chicago
- Sep 2027A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for TransplantPhase 3 · Fondazione EMN Italy Onlus
- Nov 2027Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple MyelomaPhase 3 · University of Chicago
- Nov 2026A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaPhase 1/2 · BeOne Medicines
- Nov 2026Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung CancerPhase 1 · City of Hope Medical Center
- Dec 2026Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaPhase 2 · University of Washington
- Feb 2027A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple MyelomaPhase 2 · University of Miami
- Apr 2027A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaPhase 2 · Sanofi
- May 2027Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MMPhase 2 · Andrew Yee, MD
- May 2027Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary DiseasePhase 2 · Roswell Park Cancer Institute
Studies
Open first, then newest update. How each study uses carfilzomib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 157
- Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump TherapyNot yet recruitingPhase 1National Cancer Institute (NCI)NCT07715903Written as CarfilzomibHow we know
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingPhase 1K36 Therapeutics, Inc.NCT05651932Written as Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)How we know
- A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)RecruitingPhase 3Regeneron PharmaceuticalsNCT07222761Written as CarfilzomibHow we know
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingPhase 1/2BeOne MedicinesNCT04973605Written as CarfilzomibHow we know
- Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaRecruitingPhase 1/2Wake Forest University Health SciencesNCT04822337Written as Carfilzomib, Lenalidomide, Dexamethasone, Belantamab MafodotinHow we know
- Treatment of Antibody-Mediated Rejection (ABMR) With CarBelRecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06918990Written as CarfilzomibHow we know
- Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaRecruitingPhase 2University of ChicagoNCT05789303Written as CarfilzomibHow we know
- Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple MyelomaRecruitingPhase 1Hackensack Meridian HealthNCT03909412Written as CarfilzomibHow we know
- A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingPhase 2Hackensack Meridian HealthNCT04661137Written as CarfilzomibHow we know
- Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingPhase 1/2Natalie CallanderNCT07479979Written as CarfilzomibHow we know
- Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary DiseaseRecruitingPhase 2Roswell Park Cancer InstituteNCT06627751Written as CarfilzomibHow we know
- KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS SyndromeRecruitingPhase 2Shanghai Changzheng HospitalNCT07652879Written as CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONEHow we know
- Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung CancerRecruitingPhase 1City of Hope Medical CenterNCT06249282Written as CarfilzomibHow we know
- Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary DiseaseRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06793475Written as CarfilzomibHow we know
- Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingPhase 4The First Affiliated Hospital of Soochow UniversityNCT06409702Written as CarfilzomibHow we know
- Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaRecruitingPhase 2Wuhan Union Hospital, ChinaNCT06140966Written as CarfilzomibHow we know
- Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMMNot yet recruitingPhase 2Dong-A University HospitalNCT05909826Written as CarfilzomibHow we know
- A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)Enrolling by invitationPhase 2Landspitali University HospitalNCT03815279Written as CarfilzomibHow we know
- An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma PatientsActive, not recruitingPhase 2Nantes University HospitalNCT03606577Written as CarfilzomibHow we know
- Carfilzomib and Belatacept for DesensitizationActive, not recruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT05017545Written as carfilzomibHow we know
See all 157 studies that test carfilzomib →
Given beside what is tested · 58 — carfilzomib is usual care or a partner of the new treatment
- Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07605416Written as CarfilzomibHow we know
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as CarfilzomibHow we know
- A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)RecruitingPhase 3Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06615479Written as CarfilzomibHow we know
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingPhase 1/2AbbVieNCT06892522Written as CarfilzomibHow we know
- International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabEnrolling by invitationPhase 2SanofiNCT05669989Written as CarfilzomibHow we know
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)RecruitingPhase 2GlaxoSmithKlineNCT07227311Written as CarfilzomibHow we know
- SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1Roswell Park Cancer InstituteNCT06622005Written as CarfilzomibHow we know
- A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd RegimenNot yet recruitingPhase 4The First Affiliated Hospital of Soochow UniversityNCT07709884Written as CarfilzomibHow we know
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingPhase 1/2Karyopharm Therapeutics IncNCT02343042Written as CarfilzomibHow we know
- Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple MyelomaRecruitingPhase 2Benjamin T Diamond, MDNCT05896228Written as CarfilzomibHow we know
- A Study of DaratumumabActive, not recruitingPhase 3Janssen Research & Development, LLCNCT05438043Written as CarfilzomibHow we know
- A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple MyelomaActive, not recruitingPhase 1Janssen Research & Development, LLCNCT05050097Written as CarfilzomibHow we know
- KRDI in Transplant-Eligible MMActive, not recruitingPhase 2Massachusetts General HospitalNCT04430894Written as CarfilzomibHow we know
- Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT01863550Written as CarfilzomibHow we know
- Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple MyelomaActive, not recruitingPhase 2University of Colorado, DenverNCT04925193Written as CarfilzomibHow we know
- A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple MyelomaTerminatedPhase 1/2Hoffmann-La RocheNCT06055075Written as CarfilzomibHow we know
- A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)Active, not recruitingPhase 3Bristol-Myers SquibbNCT05552976Written as CarfilzomibHow we know
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple MyelomaActive, not recruitingPhase 1PfizerNCT05675449Written as CarfilzomibHow we know
- CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple MyelomaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03798678Written as CarfilzomibHow we know
- Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple MyelomaCompletedPhase 1Thomas Martin, MDNCT02332850Written as CarfilzomibHow we know
Showing 20 of 58.
As the comparator · 8 — what is tested is compared with carfilzomib
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingPhase 3Hoffmann-La RocheNCT07555938Written as CarfilzomibHow we know
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaRecruitingPhase 3AbbVieNCT07728188Written as CarfilzomibHow we know
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)RecruitingPhase 3PfizerNCT06152575Written as CarfilzomibHow we know
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First RelapseRecruitingPhase 2National Cancer Institute (NCI)NCT06948084Written as CarfilzomibHow we know
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After TreatmentRecruitingPhase 1/2National Cancer Institute (NCI)NCT07463807Written as CarfilzomibHow we know
- A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)RecruitingPhase 3AstraZenecaNCT07391657Written as CarfilzomibHow we know
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaActive, not recruitingPhase 3Kite, A Gilead CompanyNCT06413498Written as CarfilzomibHow we know
- A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnPhase 3CelgeneNCT06232707Written as CarfilzomibHow we know
What changed recently
From the registry's own updates since Oct 21, 2026.
Started recruiting1
Results posted1
Codes
What other systems call carfilzomib · ClinicalTrials.gg INT005194
- MeSH (NLM) C524865carfilzomibOne source NLM
- UNII (FDA) 72X6E3J5ARCARFILZOMIBConfirmed FDA, NLM, Wikidata
- RxNorm 1302966Confirmed FDA, Wikidata
- Wikidata Q15366934carfilzomibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C52196CarfilzomibOne source FDA
- DrugBank DB08889One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C524865 | carfilzomib | One source NLM |
| UNII (FDA) | 72X6E3J5AR | CARFILZOMIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1302966 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15366934 | carfilzomib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C52196 | Carfilzomib | One source FDA |
| DrugBank | DB08889 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.